Journal of Cellular Biochemistry · 2008 · 80 citations · 36 references
MedicineOncologyPharmacologyCell SignalingMolecular OncologySignal TransductionCancer Cell SignalingHer2-positive Breast CancerOncogenic Signaling PathwaysSignal Transduction In CancerCancer Cell Survival SignalingFlavonoid Pathway RegulationHsp90 Chaperone SystemPhytochemicals In Cancer PreventionPolyphenol ChemopreventionProteasome InhibitorsTyrosine Kinase InhibitionTyrosine Kinase Receptors
Her-2/neu (ErbB2) is a transmembrane tyrosine kinase and acts as a co-receptor for the other EGFR family members. It is well known that high expression of Her-2/neu is associated with a poor prognosis in breast cancer. Quercetin, a flavonoid present in many vegetables and fruits, has been studied extensively as a chemoprevention agent in several cancer models. In this study, we observed that quercetin decreased the level of Her-2/neu protein in time- and dose-dependent manners and also inhibited the downstream survival PI3K-Akt signaling pathway in Her-2/neu-overexpressing breast cancer SK-Br3 cells. We also observed that quercetin induced polyubiquitination of Her-2/neu. When the proteasome pathway was blocked by MG-132 during quercetin treatment, accumulation of the NP-40 insoluble form of Her-2/neu occurred. Interestingly, data from immunocomplex studies revealed that quercetin promoted interaction between Her-2/neu and Hsp90 which is a molecular chaperone involved in stabilization of Her-2/neu. In this condition, inhibition of Hsp90 activity by a specific inhibitor, geldanamycin (GA), or intracellular ATP depletion caused dissociation of Hsp90 from Her-2/neu and promoted ubiquitination and down-regulation of Her-2/neu protein. In addition, the carboxyl terminus of Hsc70-interacting protein (CHIP), a chaperone-dependent E3 ubiquitin ligase, played a crucial role in the quercetin-induced ubiquitination of Her-2/neu. Inhibition of tyrosine kinase activity of Her-2/neu by quercetin could indicate an lateration in the Her-2/neu structure which promotes CHIP recruitments and down-regulation of Her-2/neu. We believe that by using quercetin, new therapeutic strategies can be developed to treat Her-2/neu overexpressing cancers.
36
Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science · 1987 · 11.7K citations
Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer
Dennis J. Slamon, William Godolphin, Lovell A. Jones et al. · Science · 1989 · 6.9K citations
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth M. Ward et al. · CA A Cancer Journal for Clinicians · 2006 · 5.3K citations · Full text
José Baselga, Debu Tripathy, John Mendelsohn et al. · Journal of Clinical Oncology · 1996 · 1.4K citations
Medicine, Oncology, Pharmacology +17